Nat. Immunol. 16, 448–457 (2015); published online 21 April 2015; corrected after print 17 August 2017
In the version of this article initially published, some of the labels in Figure 4a,b were incorrect. In Figure 4a, in the group of IL-6 blockers (top right), 'ALX-0061' should be removed and 'Siltuximab' and 'MEDI 5117' should be added, and in the group of IL-6R blockers (middle right), 'Siltuximab' and 'ALD518' should be removed and 'ALX-0061' should be added. In Figure 4b, in the group of inhibitors at bottom left, 'MEDI 5517' should be revised to 'MEDI 5117'. These errors have been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/ni.3153
Rights and permissions
About this article
Cite this article
Hunter, C., Jones, S. Correction: Corrigendum: IL-6 as a keystone cytokine in health and disease. Nat Immunol 18, 1271 (2017). https://doi.org/10.1038/ni1117-1271b
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni1117-1271b
This article is cited by
-
Clinical characteristics of bipolar 1 disorder in relation to interleukin-6: a cross-sectional study among Egyptian patients
Middle East Current Psychiatry (2023)
-
Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children
Journal of Cancer Research and Clinical Oncology (2022)
-
Down-regulation of aryl hydrocarbon receptor intensifies carcinogen-induced retinal lesion via SOCS3-STAT3 signaling
Cell Biology and Toxicology (2020)